MX2015016513A - Bisulfato del inhibidor de la janus quinasa (jak) y metodo de preparacion para el mismo. - Google Patents

Bisulfato del inhibidor de la janus quinasa (jak) y metodo de preparacion para el mismo.

Info

Publication number
MX2015016513A
MX2015016513A MX2015016513A MX2015016513A MX2015016513A MX 2015016513 A MX2015016513 A MX 2015016513A MX 2015016513 A MX2015016513 A MX 2015016513A MX 2015016513 A MX2015016513 A MX 2015016513A MX 2015016513 A MX2015016513 A MX 2015016513A
Authority
MX
Mexico
Prior art keywords
bisulfate
jak
inhibitor
preparation
method therefor
Prior art date
Application number
MX2015016513A
Other languages
English (en)
Inventor
Piaoyang Sun
Guaili Wu
Xiaohui Gao
Lingjia Shen
Original Assignee
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co filed Critical Jiangsu Hengrui Medicine Co
Publication of MX2015016513A publication Critical patent/MX2015016513A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se relaciona con un bisulfato de un inhibidor de la Janus quinasa (JAK) y un método de preparación para el mismo. Más específicamente, la presente invención se relaciona con un bisultato de (3aR, 5s, 6aS) -N-(3-metoxil-1,2,4-t iadiazol-5-il)-5-(metil(7H-pirrolo[2,3-d]pirimidin-4-il)amino)hex ahidrociclopenta[c]pirrol-2 (1H) -formamida mostrado en la fórmula (I), un método de preparación para el mismo, y una aplicación del mismo. El bisulfato mostrado en la fórmula (I) se puede utilizar también como un inhibidor de la Janus quinasa (JAK) en trabajo clínico, para tratar artritis reumática o artritis reumatoide. (ver Fórmula).
MX2015016513A 2013-06-07 2014-05-05 Bisulfato del inhibidor de la janus quinasa (jak) y metodo de preparacion para el mismo. MX2015016513A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201310227683 2013-06-07
PCT/CN2014/076794 WO2014194741A1 (zh) 2013-06-07 2014-05-05 一种jak激酶抑制剂的硫酸氢盐及其制备方法

Publications (1)

Publication Number Publication Date
MX2015016513A true MX2015016513A (es) 2016-04-15

Family

ID=52007520

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015016513A MX2015016513A (es) 2013-06-07 2014-05-05 Bisulfato del inhibidor de la janus quinasa (jak) y metodo de preparacion para el mismo.

Country Status (16)

Country Link
US (1) US9422300B2 (es)
EP (1) EP3006445B1 (es)
JP (1) JP6323885B2 (es)
KR (1) KR102275326B1 (es)
CN (1) CN104470927B (es)
AU (1) AU2014277506B2 (es)
BR (1) BR112015029463B1 (es)
CA (1) CA2913194C (es)
ES (1) ES2655074T3 (es)
HK (1) HK1206026A1 (es)
HU (1) HUE036533T2 (es)
MX (1) MX2015016513A (es)
PT (1) PT3006445T (es)
RU (1) RU2665680C2 (es)
TW (1) TWI641609B (es)
WO (1) WO2014194741A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105566327A (zh) 2014-10-09 2016-05-11 江苏恒瑞医药股份有限公司 一种jak激酶抑制剂的硫酸氢盐的i型结晶及其制备方法
BR112017007953B1 (pt) * 2014-11-05 2023-12-05 Jiangsu Hengrui Medicine Co., Ltd. Forma cristalina ii do bissulfato inibidor de jak quinase, seu uso e seu método de preparação, e composição farmacêutica
JP6875407B2 (ja) * 2016-02-19 2021-05-26 ジエンス ヘンルイ メデイシンカンパニー リミテッドJiangsu Hengrui Medicine Co.,Ltd. Jakキナーゼ阻害剤またはその薬剤的に許容される塩を含有する医薬組成物
US10851100B2 (en) 2016-11-23 2020-12-01 Jiangsu Hengrui Medicine Co., Ltd. Preparation method for and intermediate of pyrrolo six-membered heteroaromatic ring derivative
CN108779122B (zh) * 2017-01-20 2021-01-15 江苏恒瑞医药股份有限公司 一种jak激酶抑制剂的硫酸氢盐的晶型及其制备方法
US11241378B2 (en) 2017-11-20 2022-02-08 Jiangsu Hengrui Medicine Co., Ltd. Pharmaceutical JAK kinase inhibitor and diethylene glycol composition for topical administration and preparation method therefor
BR112021008742A2 (pt) * 2018-11-05 2021-08-10 Avista Pharma Solutions, Inc. compostos químicos
CN111205290B (zh) * 2018-11-22 2021-10-08 江苏恒瑞医药股份有限公司 一种jak激酶抑制剂的结晶形式及其制备方法
CN111440127B (zh) * 2019-01-17 2022-07-26 青岛农业大学 一种噻唑酰胺类化合物及其制备和应用
EP4025578A1 (en) * 2019-09-05 2022-07-13 Universität Bern Tricyclic janus kinase (jak) inhibitors and their use in the treatment of autoimmune diseases
CN113698404B (zh) * 2020-05-21 2023-06-16 江苏恒瑞医药股份有限公司 一种低溶剂残留的六氢环戊并[c]吡咯-2(1H)-甲酰胺化合物及其制备方法
CN116600786A (zh) 2020-07-28 2023-08-15 阿尔库缇斯生物疗法股份有限公司 含有jak抑制剂和月桂醇聚醚-4的局部制剂
MX2023005763A (es) 2020-11-17 2023-05-29 Arcutis Biotherapeutics Inc Composiciones y metodos para la administracion dermica profunda de farmacos.
CN112457272B (zh) * 2020-12-02 2022-04-19 上海再启生物技术有限公司 (3-甲氧基-1,2,4-噻二唑-5-氨基)甲酸苯酯的制备方法
US20230181591A1 (en) 2021-12-15 2023-06-15 Arcutis Biotherapeutics, Inc. Stable formulations of shr0302

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2257410T3 (es) * 2000-06-26 2006-08-01 Pfizer Products Inc. Compuestos de pirrolo(2,3-d)pirimidina como agentes inmunosupresores.
GB0307856D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Organic compounds
DE602004019198D1 (de) 2003-04-04 2009-03-12 Novartis Ag Chinolin-2-on-derivate zur behandlung von erkankungen der atemwege
US8633205B2 (en) * 2005-02-03 2014-01-21 Vertex Pharmaceuticals Incorporated Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of protein kinases
CN102822177A (zh) * 2010-02-05 2012-12-12 美国辉瑞有限公司 吡咯并[2,3-d]嘧啶脲化合物
EP2721025B1 (en) * 2011-06-16 2015-11-25 Boehringer Ingelheim International Gmbh New selective ccr2 antagonists
DK2796460T3 (en) * 2011-12-21 2018-08-27 Jiangsu Hengrui Medicine Co SEXUAL PYRROL HETEROARYL RING DERIVATIVES, METHOD OF PREPARATION AND MEDICAL APPLICATIONS THEREOF

Also Published As

Publication number Publication date
RU2665680C2 (ru) 2018-09-04
WO2014194741A1 (zh) 2014-12-11
CA2913194A1 (en) 2014-12-11
AU2014277506B2 (en) 2017-08-31
EP3006445A1 (en) 2016-04-13
CN104470927B (zh) 2016-05-04
HUE036533T2 (hu) 2018-07-30
EP3006445B1 (en) 2017-11-15
EP3006445A4 (en) 2016-11-23
RU2015156142A (ru) 2017-07-17
BR112015029463A2 (pt) 2017-07-25
US20160102098A1 (en) 2016-04-14
RU2015156142A3 (es) 2018-03-19
TWI641609B (zh) 2018-11-21
JP2016520134A (ja) 2016-07-11
CN104470927A (zh) 2015-03-25
BR112015029463B1 (pt) 2023-01-10
CA2913194C (en) 2021-03-02
TW201514180A (zh) 2015-04-16
US9422300B2 (en) 2016-08-23
AU2014277506A1 (en) 2016-01-21
ES2655074T3 (es) 2018-02-16
JP6323885B2 (ja) 2018-05-16
KR20160032021A (ko) 2016-03-23
PT3006445T (pt) 2018-01-09
HK1206026A1 (zh) 2015-12-31
KR102275326B1 (ko) 2021-07-12

Similar Documents

Publication Publication Date Title
MX2015016513A (es) Bisulfato del inhibidor de la janus quinasa (jak) y metodo de preparacion para el mismo.
CY1123637T1 (el) Αναστολεις μεθυλοτρανσφερασης αργινινης και χρησεις αυτων
MX2023006257A (es) Inhibidores de smyd.
MX2015013481A (es) Compuestos heterociclicos fusionados como inhibidores de proteina quinasa.
PH12015502041B1 (en) Heteroaryl compounds and uses thereof
MX364155B (es) Sulfonamidas como moduladores de canales de sodio.
MX2015015422A (es) Inhibidores de acetil-coa carboxilasa (acc) y usos de los mismos.
NZ750187A (en) Pyridone amides as modulators of sodium channels
MD4735B1 (ro) Derivaţi ai pirolo[2,3-d]pirimidinei ca inhibitori de Kinaze Janus-asociate (JAK)
MX368066B (es) Derivados de quinazolin-4-ona sustituida.
EP4282479A3 (en) Use of pridopidine to treat depression or anxiety
EA201591532A1 (ru) Ингибиторы carm1 и их применение
AU2014267235A8 (en) Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
EA201890820A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ДВОЙСТВЕННЫХ ИНГИБИТОРОВ DYRK1/CLK1
EA201792689A1 (ru) Производные 2-(пиразолопиридин-3-ил)пиримидина в качестве ингибиторов jak
PH12015502118A1 (en) Pyridin-4-yl derivatives
TR201901348T4 (tr) Metap-2 inhibitörleri olarak pirolidinon türevleri.
PH12015502409A1 (en) Pyrrolo[2,3-d]pyrimidine derivatives as cb2 receptor agonists
TW201613931A (en) Form crystal of bisulfate of janus kinase (JAK) inhibitor and preparation method thereof
PH12016500347A1 (en) Triazolopyridine compounds, compositions and methods of use thereof
MX2015013414A (es) N-(2-ciano heterociclil)pirazolo piridonas como inhibidores de janus quinasa.
MX2017009600A (es) Derivados de 2-fenil-3h-imidazo[4,5-b]piridina utiles como inhibidores de actividad de receptor huerfano similar a tirosina cinasa (ror1) de tirosina cinasa de mamifero.
WO2015061686A3 (en) Retinoid x receptor-gamma agonists and retinoid x receptor-alpha antagonists for treatment of cancer
MX2015013740A (es) Derivados de pirazolnaftridinona, preparacion y uso terapautico de los mismos.
EA201600123A1 (ru) Производные 1-(пиперазин-1-ил)-2-([1,2,4]триазол-1-ил)этанона

Legal Events

Date Code Title Description
FG Grant or registration